{"id":"NCT01280981","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding","officialTitle":"A Multi-center, Open Label Extension Study to Evaluate the Safety of an Oral Dose of Tranexamic Acid (XP12B) Administered Three Times Daily During Menstruation for the Treatment of Menorrhagia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2011-01-21","resultsPosted":"2011-07-26","lastUpdate":"2011-07-26"},"enrollment":288,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Menorrhagia"],"interventions":[{"type":"DRUG","name":"Tranexamic acid","otherNames":["XP12B","Lysteda"]}],"arms":[{"label":"Tranexamic acid","type":"EXPERIMENTAL"}],"summary":"This was a multicenter, open-label extension study for subjects completing either of 2 pivotal efficacy studies (NCT00401193 or NCT00386308). The study consisted of a treatment phase of 9 menstrual periods to assess the safety of tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation. After the last treatment period, a follow-up phone call occurred approximately 30 days (range 25 to 35 days) after the last dose of study drug.","primaryOutcome":{"measure":"Participants With Treatment-Emergent Adverse Events (AEs)","timeFrame":"Day 1 to up to Month 9","effectByArm":[{"arm":"Tranexamic Acid","deltaMin":218,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":23},"locations":{"siteCount":92,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":260},"commonTop":["Headache","Back pain","Viral upper respiratory tract infection","Sinusitis","Pain in extremity"]}}